294 related articles for article (PubMed ID: 19151568)
1. [Evaluation of efficacy and safety of adjuvant analgesics for peripheral neuropathy induced by cancer chemotherapy in digestive cancer patients-a pilot study].
Yano T; Yamane H; Fukuoka R; Ninomiya T; Umemura S; Suzuki S; Saeki H; Hanaoka T; Katou T; Itoh K; Fujita T; Kamei H
Gan To Kagaku Ryoho; 2009 Jan; 36(1):83-7. PubMed ID: 19151568
[TBL] [Abstract][Full Text] [Related]
2. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
3. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T
Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767
[TBL] [Abstract][Full Text] [Related]
5. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
6. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
[TBL] [Abstract][Full Text] [Related]
7. Therapy of chemotherapy-induced peripheral neuropathy.
Kaley TJ; Deangelis LM
Br J Haematol; 2009 Apr; 145(1):3-14. PubMed ID: 19170681
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced neuropathy.
Windebank AJ; Grisold W
J Peripher Nerv Syst; 2008 Mar; 13(1):27-46. PubMed ID: 18346229
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
[TBL] [Abstract][Full Text] [Related]
10. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
[TBL] [Abstract][Full Text] [Related]
11. A pilot study on the relation between cisplatin neuropathy and vitamin E.
Bove L; Picardo M; Maresca V; Jandolo B; Pace A
J Exp Clin Cancer Res; 2001 Jun; 20(2):277-80. PubMed ID: 11484987
[TBL] [Abstract][Full Text] [Related]
12. The effect of diabetes on oxaliplatin-induced peripheral neuropathy.
Uwah AN; Ackler J; Leighton JC; Pomerantz S; Tester W
Clin Colorectal Cancer; 2012 Dec; 11(4):275-9. PubMed ID: 22682776
[TBL] [Abstract][Full Text] [Related]
13. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
[TBL] [Abstract][Full Text] [Related]
14. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
Yoshimura T; Hirade K; Iihara H; Ishihara M; Komori Y; Okayasu S; Matsuura K; Yasuda T; Itoh Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
16. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.
Kautio AL; Haanpää M; Leminen A; Kalso E; Kautiainen H; Saarto T
Anticancer Res; 2009 Jul; 29(7):2601-6. PubMed ID: 19596934
[TBL] [Abstract][Full Text] [Related]
17. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
Hausheer FH; Schilsky RL; Bain S; Berghorn EJ; Lieberman F
Semin Oncol; 2006 Feb; 33(1):15-49. PubMed ID: 16473643
[TBL] [Abstract][Full Text] [Related]
19. Persistent neuropathy after treatment with cisplatin and oxaliplatin.
Brouwers EE; Huitema AD; Boogerd W; Beijnen JH; Schellens JH
Acta Oncol; 2009; 48(6):832-41. PubMed ID: 19308757
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
Tofthagen C; McAllister RD; McMillan SC
Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
